Drug Trial Radar · NCT00856284
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Dec 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,639
Actual
Start
Mar 2009
Primary completion
Oct 2012
Study completion Oct 2012
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 5, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
Conditions
- Type 2 Diabetes Mellitus
Interventions
AlogliptinDrug
Alogliptin tablets
MetforminDrug
Metformin tablets
GlipizideDrug
Glipizide tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52Time frame: Baseline and Week 52
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104Time frame: Baseline and Week 104
Locations
261 sites in 32 countries. Site status is shown where the registry gives one.
Site not named
Montgomery, Alabama
Site not named
Muscle Shoals, Alabama
Site not named
Pell City, Alabama
Site not named
Mesa, Arizona
Site not named
Peoria, Arizona
Site not named
Phoenix, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Artesia, California
Site not named
Chico, California
Site not named
Los Alamitos, California
Site not named
Mission Viejo, California
Site not named
National City, California
Site not named
Northridge, California
Site not named
Pismo Beach, California
Site not named
Riverside, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Santa Monica, California
Site not named
Tustin, California
Site not named
Arvada, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Ridgefield, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Brooksville, Florida
Site not named
New Port Richey, Florida
Site not named
North Miami Beach, Florida
Site not named
Ocala, Florida
Site not named
Opa-locka, Florida
Site not named
Orlando, Florida
Site not named
Augusta, Georgia
Site not named
Savannah, Georgia
Site not named
Addison, Illinois
Site not named
Chicago, Illinois
Site not named
Bloomington, Indiana
Site not named
Evansville, Indiana
Site not named
Indianapolis, Indiana
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.